Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
J Emerg Med. 2023 Oct;65(4):e357-e365. doi: 10.1016/j.jemermed.2023.06.007. Epub 2023 Jun 20.
Opioid overdose deaths in 2021 were the highest ever, driven by fentanyl and polysubstance use.
The aim of the study was to characterize drug use, assessed by urine drug screens (UDSs), in patients with untreated opioid use disorder (OUD) presenting to 28 emergency departments (EDs) nationally and by region.
We analyzed UDSs from patients enrolled in the CTN-0099 ED-INNOVATION (Emergency Department-Initiated Buprenorphine Validation) trial between July 12, 2020 and March 9, 2022. Participants were adult ED patients with OUD not engaged in addiction treatment with a UDS positive for an opioid, but negative for methadone. Sites were divided into "East" and "West" regions.
A UDS was available for all 925 enrolled participants, 543 from East and 382 from West. Fentanyl was in 702 specimens (76%) (n = 485 [89%] East vs. n = 217 [57%] West; p < 0.01) and was the only opioid in 269 (29%). After fentanyl, the most common opioids were morphine (presumably heroin; n = 411 [44%]; n = 192 [35%] East vs. n = 219 [57%] West; p < 0.01) and buprenorphine (n = 329 [36%]; n = 186 [35%] East vs. n = 143 [37%] West; p = 0.32). The most common drugs found with opioids were stimulants (n = 545 [59%]), tetrahydrocannabinol (n = 417 [45%]), and benzodiazepines (n = 151 [16%]). Amphetamine-type stimulants were more common in West (n = 209 [55%] vs. East (n = 125 [23%]). Cocaine was more common in East (n = 223 [41%]) vs. West (n = 82 [21%]). The presence of multiple drugs was common (n = 759 [82%]).
Most participants had UDS specimens containing multiple substances; a high proportion had fentanyl, stimulants, and buprenorphine. Regional differences were noted. Given the increased risk of death with fentanyl and polysubstance use, ED providers should be providing risk reduction counseling, treatment, and referral.
2021 年阿片类药物过量死亡人数创历史新高,这主要是由芬太尼和多种物质滥用造成的。
本研究旨在通过全国 28 家急诊部(ED)和地区的未经治疗的阿片类药物使用障碍(OUD)患者的尿液药物筛查(UDS)来描述药物使用情况。
我们分析了 2020 年 7 月 12 日至 2022 年 3 月 9 日期间参加 CTN-0099 ED-INNOVATION(ED 发起的丁丙诺啡验证)试验的患者的 UDS。参与者为患有 OUD 的成年 ED 患者,未接受阿片类药物成瘾治疗,UDS 检测到阿片类药物阳性,但美沙酮阴性。研究地点分为“东部”和“西部”两个区域。
925 名入组患者均提供了 UDS,其中东部地区 543 例,西部地区 382 例。在 702 份标本中发现了芬太尼(76%)(n=485[89%]东部 vs. n=217[57%]西部;p<0.01),且只有 269 份标本中仅含有芬太尼(29%)。在芬太尼之后,最常见的阿片类药物是吗啡(推测为海洛因;n=411[44%];n=192[35%]东部 vs. n=219[57%]西部;p<0.01)和丁丙诺啡(n=329[36%];n=186[35%]东部 vs. n=143[37%]西部;p=0.32)。与阿片类药物一起发现的最常见药物是兴奋剂(n=545[59%])、四氢大麻酚(n=417[45%])和苯二氮䓬类药物(n=151[16%])。安非他命类兴奋剂在西部地区更为常见(n=209[55%]),而在东部地区则较少见(n=125[23%])。可卡因在东部地区更为常见(n=223[41%]),而在西部地区则较少见(n=82[21%])。多种药物同时存在的情况很常见(n=759[82%])。
大多数参与者的 UDS 标本中含有多种物质;很大一部分人同时使用了芬太尼、兴奋剂和丁丙诺啡。注意到了地区差异。鉴于芬太尼和多种物质滥用会增加死亡风险,ED 医护人员应提供风险降低咨询、治疗和转介服务。